文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

重症监护病房中的卡氏肺孢子虫肺炎:ESGCIP 和 EFISG 的多中心研究。

Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG.

机构信息

Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.

Infectious Diseases Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neurosciences, L.go R. Benzi 10, 16132, Genoa, Italy.

出版信息

Crit Care. 2023 Aug 24;27(1):323. doi: 10.1186/s13054-023-04608-1.


DOI:10.1186/s13054-023-04608-1
PMID:37620828
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10464114/
Abstract

BACKGROUND: Pneumocystis jirovecii pneumonia (PJP) is an opportunistic, life-threatening disease commonly affecting immunocompromised patients. The distribution of predisposing diseases or conditions in critically ill patients admitted to intensive care unit (ICU) and subjected to diagnostic work-up for PJP has seldom been explored. MATERIALS AND METHODS: The primary objective of the study was to describe the characteristics of ICU patients subjected to diagnostic workup for PJP. The secondary objectives were: (i) to assess demographic and clinical variables associated with PJP; (ii) to assess the performance of Pneumocystis PCR on respiratory specimens and serum BDG for the diagnosis of PJP; (iii) to describe 30-day and 90-day mortality in the study population. RESULTS: Overall, 600 patients were included in the study, of whom 115 had presumptive/proven PJP (19.2%). Only 8.8% of ICU patients subjected to diagnostic workup for PJP had HIV infection, whereas hematological malignancy, solid tumor, inflammatory diseases, and solid organ transplants were present in 23.2%, 16.2%, 15.5%, and 10.0% of tested patients, respectively. In multivariable analysis, AIDS (odds ratio [OR] 3.31; 95% confidence interval [CI] 1.13-9.64, p = 0.029), non-Hodgkin lymphoma (OR 3.71; 95% CI 1.23-11.18, p = 0.020), vasculitis (OR 5.95; 95% CI 1.07-33.22, p = 0.042), metastatic solid tumor (OR 4.31; 95% CI 1.76-10.53, p = 0.001), and bilateral ground glass on CT scan (OR 2.19; 95% CI 1.01-4.78, p = 0.048) were associated with PJP, whereas an inverse association was observed for increasing lymphocyte cell count (OR 0.64; 95% CI 0.42-1.00, p = 0.049). For the diagnosis of PJP, higher positive predictive value (PPV) was observed when both respiratory Pneumocystis PCR and serum BDG were positive compared to individual assay positivity (72% for the combination vs. 63% for PCR and 39% for BDG). Cumulative 30-day mortality and 90-day mortality in patients with presumptive/proven PJP were 52% and 67%, respectively. CONCLUSION: PJP in critically ill patients admitted to ICU is nowadays most encountered in non-HIV patients. Serum BDG when used in combination with respiratory Pneumocystis PCR could help improve the certainty of PJP diagnosis.

摘要

背景:卡氏肺孢子虫肺炎(PJP)是一种机会性的、危及生命的疾病,常见于免疫功能低下的患者。在重症监护病房(ICU)接受诊断性检查的危重症患者中,易患疾病或情况的分布情况很少被探讨。

材料和方法:本研究的主要目的是描述接受卡氏肺孢子虫诊断性检查的 ICU 患者的特征。次要目标是:(i)评估与 PJP 相关的人口统计学和临床变量;(ii)评估呼吸道标本和血清 BDG 中卡氏肺孢子虫 PCR 对 PJP 的诊断性能;(iii)描述研究人群的 30 天和 90 天死亡率。

结果:总体而言,共有 600 名患者纳入研究,其中 115 例患者有疑似/确诊的 PJP(19.2%)。仅 8.8%的接受 PJP 诊断性检查的 ICU 患者存在 HIV 感染,而血液系统恶性肿瘤、实体瘤、炎症性疾病和实体器官移植在接受检查的患者中分别占 23.2%、16.2%、15.5%和 10.0%。多变量分析显示,艾滋病(比值比 [OR] 3.31;95%置信区间 [CI] 1.13-9.64,p=0.029)、非霍奇金淋巴瘤(OR 3.71;95% CI 1.23-11.18,p=0.020)、血管炎(OR 5.95;95% CI 1.07-33.22,p=0.042)、转移性实体瘤(OR 4.31;95% CI 1.76-10.53,p=0.001)和 CT 扫描双侧磨玻璃影(OR 2.19;95% CI 1.01-4.78,p=0.048)与 PJP 相关,而淋巴细胞计数增加呈负相关(OR 0.64;95% CI 0.42-1.00,p=0.049)。对于 PJP 的诊断,与单个检测阳性相比,呼吸道卡氏肺孢子虫 PCR 和血清 BDG 均阳性时观察到更高的阳性预测值(PPV)(联合检测为 72%,PCR 为 63%,BDG 为 39%)。疑似/确诊 PJP 患者的 30 天累积死亡率和 90 天死亡率分别为 52%和 67%。

结论:目前,在入住 ICU 的危重症患者中,卡氏肺孢子虫肺炎最常发生在非 HIV 患者中。当与呼吸道卡氏肺孢子虫 PCR 联合使用时,血清 BDG 有助于提高 PJP 诊断的确定性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f91f/10464114/c5c0c5fd1076/13054_2023_4608_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f91f/10464114/03af1cc32712/13054_2023_4608_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f91f/10464114/c5c0c5fd1076/13054_2023_4608_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f91f/10464114/03af1cc32712/13054_2023_4608_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f91f/10464114/c5c0c5fd1076/13054_2023_4608_Fig2_HTML.jpg

相似文献

[1]
Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG.

Crit Care. 2023-8-24

[2]
Identifying optimal serum 1,3-β-D-Glucan cut-off for diagnosing Pneumocystis Jirovecii Pneumonia in non-HIV patients in the intensive care unit.

BMC Infect Dis. 2024-9-20

[3]
Negative serum (1,3) -β-D-glucan has a low power to exclude Pneumocystis jirovecii pneumonia (PJP) in HIV-uninfected patients with positive qPCR.

Ann Clin Microbiol Antimicrob. 2023-11-20

[4]
Diagnostic accuracy of serum (1-3)-β-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis.

Clin Microbiol Infect. 2020-9

[5]
Metagenomic next-generation sequencing promotes diagnosis and treatment of Pneumocystis jirovecii pneumonia in non-HIV infected children: a retrospective study.

BMC Pulm Med. 2024-7-12

[6]
Evaluation of a Turbidimetric β-d-Glucan Test for Detection of Pneumocystis jirovecii Pneumonia.

J Clin Microbiol. 2018-6-25

[7]
Pneumocystis jirovecii pneumonia in AIDS and non-AIDS immunocompromised patients - an update.

J Infect Dev Ctries. 2018-10-31

[8]
Clinical Performance of BAL Metagenomic Next-Generation Sequence and Serum (1,3)-β-D-Glucan for Differential Diagnosis of Pneumonia and Colonisation.

Front Cell Infect Microbiol. 2021

[9]
Pneumocystis jirovecii pneumonia: a case report.

J Med Case Rep. 2024-2-12

[10]
[Pneumocystis jirovecii and quantitative PCR: Pneumonia or colonization?].

Rev Mal Respir. 2020-4

引用本文的文献

[1]
Mortality of pneumonia in intensive care units: a post-hoc analysis of an international multicenter study by ESGCIP and EFISG.

Ann Med. 2025-12

[2]
Explainable machine learning model for prediction of 28-day all-cause mortality in immunocompromised patients in the intensive care unit: a retrospective cohort study based on MIMIC-IV database.

Eur J Med Res. 2025-5-3

[3]
Epidemiology and Clinical Relevance of in Non-Human Immunodeficiency Virus Patients at a Tertiary Care Center in Central Europe: A 3-Year Retrospective Study.

J Clin Med. 2025-4-19

[4]
Association of obesity on short- and long-term survival in patients with moderate to severe pneumonia-related ARDS: a retrospective cohort study.

BMC Pulm Med. 2025-4-3

[5]
Establishment of an RPA-CRISPR/Cas12a combined diagnostic system for Pneumocystis jirovecii pneumonia.

PLoS Negl Trop Dis. 2025-3-18

[6]
Viral reactivations and fungal infections in nonresolving acute respiratory distress syndrome.

Eur Respir Rev. 2025-2-19

[7]
Development and assessment of a mortality risk prediction nomogram model for pneumocystis disease in ICU within 28 days.

Sci Rep. 2025-1-18

[8]
Prognostic role of early blood gas variables in critically ill patients with Pneumocystis jirovecii pneumonia: a retrospective analysis.

Crit Care. 2024-9-27

[9]
Identifying optimal serum 1,3-β-D-Glucan cut-off for diagnosing Pneumocystis Jirovecii Pneumonia in non-HIV patients in the intensive care unit.

BMC Infect Dis. 2024-9-20

[10]
Fungal infections in immunocompromised critically ill patients.

J Intensive Med. 2024-3-16

本文引用的文献

[1]
A Wide Database for a Multicenter Study on Pneumocystis jirovecii Pneumonia in Intensive Care Units.

Stud Health Technol Inform. 2022-5-25

[2]
Non-HIV-infected patients with Pneumocystis pneumonia in the intensive care unit: A bicentric, retrospective study focused on predictive factors of in-hospital mortality.

Clin Respir J. 2022-2

[3]
Quantitative PCR to Discriminate Between Pneumonia and Colonization in HIV and Non-HIV Immunocompromised Patients.

Front Microbiol. 2021-10-20

[4]
Non-invasive diagnosis of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis.

Clin Microbiol Infect. 2022-1

[5]
Pneumocystis jirovecii Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus.

Clin Infect Dis. 2021-3-12

[6]
Host Factors and Outcomes in Hospitalizations for Pneumocystis Jirovecii Pneumonia in the United States.

Mayo Clin Proc. 2021-2

[7]
Comparative performance evaluation of Wako β-glucan test and Fungitell assay for the diagnosis of invasive fungal diseases.

PLoS One. 2020-7-29

[8]
Epidemiology of Pneumonia and (Non-)use of Prophylaxis.

Front Cell Infect Microbiol. 2020-5-15

[9]
Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches.

Med Mycol. 2020-11-10

[10]
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.

Clin Infect Dis. 2020-9-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索